All Drug Delivery articles – Page 11
-
ArticleA Guide to DNA Damage Response and Innate Immunity
In this guide, we provide an overview of the DDR and innate immune pathway and describe Transcreener Assays and Assay Systems for key targets.
-
ArticleBiological robots: a new therapeutic tool
Anthrobots derived from human tracheal cells could perform therapeutic work without initiating an immune response.
-
WhitepaperArticle: Tips and Tricks for Leveraging Advanced Flow Cytometry
Tips and tricks for fully leveraging Advanced Flow Cytometry.
-
ArticleUnique self-activating proteins for drug discovery
Explore cutting-edge hit-to-lead insights through exclusive interviews and studies by leading experts in the field.
-
NewsThe loading mechanism of bacteria injectisomes is now understood
Proximity labelling and single-particle tracking demonstrated that effectors in bacteria bind to mobile injectisome components.
-
ArticleWomen in STEM with Dr Catherine Sheehan
In this special December edition of Women in STEM, we are privileged to feature Dr Catherine Sheehan, a distinguished figure whose journey in the field of STEM has been marked by passion, resilience, and impactful contributions. We explore her experiences, challenges faced, and the transformative impact of her work in ...
-
ArticleThe future of mRNA biology and AI convergence
In the rapidly evolving landscape of mRNA biology and artificial intelligence (AI), Anima Biotech stands at the forefront, a unique approach that reshapes our understanding of diseases and transforms the drug discovery process. mRNA biology holds immense potential with RNAi drugs in the market and mRNA vaccines showing promise, particularly ...
-
NewsNew lipid nanoparticles effectively deliver RNA to microglia
LNPs deliver small interfering RNA to the brain’s microglia to combat inflammation related to Alzheimer’s disease.
-
ArticleWomen in Stem with Andrea Pfeifer
This November edition of our Women in Stem series spotlights Andrea Pfeifer, CEO and Co-Founder of AC Immune SA. Dr Andrea Pfeifer co-founded AC Immune SA in 2003, since when she has served as a Director on the Board, successfully leading it to an IPO in 2016. Under her leadership, ...
-
ArticleExploring liver disease therapies
Ochre Bio is at the forefront of therapeutic innovation, focusing primarily on liver diseases. Their core mission revolves around the development of RNA therapies, primarily in the preclinical stage, using a 'human-first' approach. They employ real human tissue, such as 'liver slices' and whole human livers, in their preclinical pipeline ...
-
NewsMitochondria-targeting antibiotics reduce aging in C. elegans
Treating C. elegans with inhibitors of small or large mitochondrial ribosomes extended their median lifespan.
-
ArticleThe role of STRIs in cancer
Within cancer cells, the eIF4F complex's dysregulation amplifies the translation of cancer-promoting proteins, establishing it as a critical juncture in malignancy and resistance to treatment. eFFECTOR Therapeutics has responded with Selective Translation Regulator Inhibitors (STRIs). These STRIs are precision instruments dismantling the foundations of tumour growth, immune evasion, and resistance ...
-
NewsMacrophage phenotype insights could improve immunotherapy
A certain macrophage phenotype is more effective than another phenotype commonly used in cell therapy for infiltrating tumours.
-
ArticleBreaking new ground in endometriosis treatment
Endometriosis is a debilitating condition that affects millions of women worldwide, causing chronic pain, infertility, and a host of other distressing symptoms. Current treatments offer limited relief, but they do not address the cause of the disease. Professor Hugo Vankelecom, at the helm of the CurE-me project, is on a ...
-
NewsSynthetic proteins key to modular nanoparticle design
Researchers have been able to customise nanoparticles to target biological entities, like tumours and viruses.
-
News
Explosive cell death: inflammation-causing gene
WEHI researchers have found that a genetic change of MLKL increases risk of uncontrolled inflammatory response
-
WebinarComplete aggregate and particle characterisation of protein, gene and cell therapies
Join us to learn about the importance of subvisible particle characterisation for better product stability, ensuring patient safety from early-phase development through USP 788 lot release testing.
-
ArticleAntibody-drug conjugates payloads: then, now and next
Dr Nicolas Camper at CDMO Abzena and colleagues offer insight into the landscape of antibody-drug conjugates and how the therapy is evolving.
-
ArticleAddressing increasingly resistant drugs by infectious agents
Infectious agents' drug resistance is a complex challenge affecting survival. Understanding their mechanisms in vectors, the potential of plant-derived treatments, and roles of nucleic acids and biochemical compounds is crucial for effective therapy, requiring collaborative international research through the One Health Initiative.
-
ArticleTherapeutic frontiers: the potential of RRx-001 and AdAPT-001
Meet RRx-001 (nibrozetone) and AdAPT-001—two cutting-edge compounds crafted by EpicentRx. In this Q&A session with Dr Bryan Oronsky, Chief Development Officer at EpicentRx, we discover novel mechanisms, diverse applications, and game-changing impact on cancer treatment and beyond.